KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Cost of Revenue: 2022-2024

Historic Cost of Revenue for Recursion Pharmaceuticals (RXRX) over the last 3 years, with Dec 2024 value amounting to $45.2 million.

  • Recursion Pharmaceuticals' Cost of Revenue rose 21.59% to $14.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $69.5 million, marking a year-over-year increase of 64.14%. This contributed to the annual value of $45.2 million for FY2024, which is 6.22% up from last year.
  • According to the latest figures from FY2024, Recursion Pharmaceuticals' Cost of Revenue is $45.2 million, which was up 6.22% from $42.6 million recorded in FY2023.
  • In the past 5 years, Recursion Pharmaceuticals' Cost of Revenue ranged from a high of $48.3 million in FY2022 and a low of $42.6 million during FY2023.
  • In the last 3 years, Recursion Pharmaceuticals' Cost of Revenue had a median value of $45.2 million in 2024 and averaged $45.4 million.
  • As far as peak fluctuations go, Recursion Pharmaceuticals' Cost of Revenue decreased by 11.78% in 2023, and later grew by 6.22% in 2024.
  • Recursion Pharmaceuticals' Cost of Revenue (Yearly) stood at $48.3 million in 2022, then decreased by 11.78% to $42.6 million in 2023, then increased by 6.22% to $45.2 million in 2024.